The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; none of the 11 sources its claims cite is checked for support yet.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Open accessAbstract
Background In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 [177 Lu]Lu-PSMA-617 (vipivotide tetraxetan) improved radiographic progression-free survival and overall survival when added to protocol-permitted standard of care in patients with metastatic castration-resistant prostate cancer. Here, we report additional health-related quality of life (HRQOL), pain, and symptomatic skeletal event results.Methods This multicentre, open-label, randomised, phase 3 trial was conducted at 84 cancer centres in nine countries in North America and Europe. Eligible patients were aged 18 years or older; had progressive PSMA-positive metastatic castration-resistant prostate cancer; an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; and had previously received of at least one androgen receptor pathway inhibitor and one or two taxane-containing regimens. Patients were randomly assigned (2:1) to receive either [177 Lu]Lu-PSMA-617 plus protocol-permitted standard of care ([177 Lu]Lu-PSMA-617 group) or standard of care alone (control group) using permuted blocks. Randomisation was stratified by baseline lactate dehydrogenase concentration, liver metastases, ECOG performance status, and androgen receptor pathway inhibitor inclusion in standard of care. Patients in the [177 Lu]Lu-PSMA-617 group received intravenous infusions of 7·4 gigabecquerel (GBq; 200 millicurie [mCi]) [177 Lu]Lu-PSMA-617 every 6 weeks for four cycles plus two optional additional cycles. Standard of care included approved hormonal treatments, bisphosphonates, and radiotherapy. The alternate primary endpoints were radiographic progression-free survival and overall survival, which have been reported. Here we report the key secondary endpoint of time to first symptomatic skeletal event, and other secondary endpoints of HRQOL assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EQ-5D-5L, and pain assessed with the Brief Pain Inventory-Short Form (BPI-SF). Patient-reported outcomes and symptomatic skeletal events were analysed in all patients who were randomly assigned after implementation of measures designed to reduce the dropout rate in the control group (on or after March 5, 2019), and safety was analysed according to treatment received in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, NCT03511664, and is active but not recruiting.Findings Between June 4, 2018, and Oct 23, 2019, 831 patients were enrolled, of whom 581 were randomly assigned to the [177 Lu]Lu-PSMA-617 group (n=385) or control group (n=196) on or after March 5, 2019, and were included in analyses of HRQOL, pain, and time to first symptomatic skeletal event. The median age of patients was 71 years (IQR 65-75) in the [177 Lu]Lu-PSMA-617 group and 72·0 years (66-76) in the control group. Median time to first symptomatic skeletal event or death was 11·5 months (95% CI 10·3-13·2) in the [177 Lu]Lu-PSMA-617 group and 6·8 months (5·2-8·5) in the control group (hazard ratio [HR] 0·50, 95% CI 0·40-0·62). Time to worsening was delayed in the [177 Lu]Lu-PSMA-617 group versus the control group for FACT-P score (HR 0·54, 0·45-0·66) and subdomains, BPI-SF pain intensity score (0·52, 0·42-0·63), and EQ-5D-5L utility score (0·65, 0·54-0·78). Grade 3 or 4 haematological adverse events included decreased haemoglobin (80 [15%] of 529 assessable patients who received [177 Lu]Lu-PSMA-617 plus standard of care vs 13 [6%] of 205 who received standard of care only), lymphocyte concentrations (269 [51%] vs 39 [19%]), and platelet counts (49 [9%] vs five [2%]). Treatment-related adverse events leading to death occurred in five (1%) patients who received [177 Lu]Lu-PSMA-617 plus standard of care (pancytopenia [n=2], bone marrow failure [n=1], subdural haematoma [n=1], and intracranial haemorrhage [n=1]) and no patients who received standard of care only.Interpretation [177 Lu]Lu-PSMA-617 plus standard of care delayed time to worsening in HRQOL and time to skeletal events compared with standard of care alone. These findings support the use of [177 Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer who received previous androgen receptor pathway inhibitor and taxane treatment.Funding Advanced Accelerator Applications (Novartis).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
26 Own result · 12 Own method · 11 Not checked yet · 7 Own interpretation · 2 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The time to improvement after worsening in BPI-SF pain intensity scale was shorter in the 177Lu-PSMA-617 arm than the control arm (appendix p 8).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HRs were in the range of 0·45 to 0·60 for all instruments, and similar delays in time to worsening in score, clinical disease progression, or death were detected in prespecified and post hoc analyses.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The time to worsening in EQ-5D-5L utility score was delayed in the 177Lu-PSMA-617 group compared with the control group, in both prespecified and post hoc analyses (figure 2C and table 1).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The predominant types of SSE were radiation to relieve bone pain, followed by spinal cord compression (table 2).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean creatinine levels remained stable over time (figure 3C).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 21/529 patients (4%) had 177Lu-PSMA-617 dose reductions owing to myelosuppression (appendix p 15).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plaindirectn = 529- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the present analyses, time to SSE or death was delayed in the 177Lu-PSMA-617 group compared versus control regardless of bone-targeted therapy use.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The largest differences between the 177Lu-PSMA-617 and control groups were for FACT-P total score and the physical, emotional, and functional well-being subscales (table 1).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Low rates of haematologic and renal toxicity were observed with 177Lu-PSMA-617 treatment.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Time to first SSE or death was delayed in subgroups with (hazard ratio [HR], 0·49; 95% confidence interval [CI]: 0·36, 0·68) and without (HR, 0·50; 95% CI: 0·37, 0·68) concurrent use of bone-targeted therapy.”
- Also stated in: § Results · plain
“Among the 310/581 (53%) patients not receiving bone-targeted therapy at baseline, the median time to first SSE or death was delayed in the 177Lu-PSMA-617 group compared with the control group (table 3 and appendix p 1).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Abstract > Findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
- It may state two separate claims as one. 14
- Probably not a substantial claim. 11
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of creatinine abnormalities of CTCAE grade 3 or above was low, and similar between the 177Lu-PSMA-617 group and the control group (appendix p 12).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Worsening was delayed across all PROs, and all subscales and domains, with the greatest difference in median time to event in BPI-SF pain intensity and FACT-P total score.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Time to HRQoL worsening was delayed with 177Lu-PSMA-617 on both the FACT-P and EQ-5D-5L, with similar HRs.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The time to worsening in EQ-5D-5L utility score of 0·10 points was also delayed in the 177Lu-PSMA-617 group compared with the control group, both when clinical disease progression or death were included in the definition and when not included (appendix p 9).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Adverse events in the “myelosuppression” and “renal effects” groupings were more frequent during randomised treatment with 177Lu-PSMA-617 plus Soc than with SoC alone, but were mainly low-grade.12”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
What the sources say
- Not checked yetcites [12] Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean haemoglobin levels and platelet counts remained stable over time (figure 3A–B).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“In VISION, the median time to first SSE or death was delayed in the 177Lu-PSMA-617 group versus control,12 and spinal cord compression, the most deleterious SSE, was numerically less frequent.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
What the sources say
- Not checked yetcites [12] Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Questionnaire completion rates were similar at the end-of-treatment visit, with data available for approximately 45% of patients in both groups (appendix p 3).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This safety profile supports 177Lu-PSMA-617 use in often elderly patients with late-stage disease29 and potentially in younger patients with earlier-stage disease.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
What the sources say
- Not checked yetcites [29] Gillessen, 2021, Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis, Proc Am Soc Clin Oncol
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The radioligand 177Lu-PSMA-617 improves quality of life and delays SSEs in patients with advanced mCRPC.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Abstract > Interpretation
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In this open-label study, patients were randomised 2:1 using an interactive response system to receive either 177Lu-PSMA-617 plus protocol-permitted SoC (177Lu-PSMA-617 group) or protocol-permitted SoC alone (control group) using a permuted block scheme.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Randomisation and masking
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients remaining on study treatment, questionnaire completion rates were high (appendix p 3).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results support the conclusion that there was no adverse effect of 177Lu-PSMA-617 on HRQoL or pain, despite the limitation that data were collected only during study treatment.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Patients who did not complete questionnaires because they died or experienced disease progression were assumed to have worsened in health-related quality of life and pain.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Safety was analysed according to treatment received in the safety analysis set, comprising all patients who received at least one dose of randomised treatment.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“PSMA-positive tumor status was determined by gallium (68Ga) gozetotide (also known as [68Ga]Ga-PSMA-11; 68Ga-PSMA-11) positron emission tomography (PET)-CT imaging during screening and evaluated by independent central review.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Study design and participants
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“The lack of double-blinding and placebo control are limitations shared by studies of other radiopharmaceuticals.30”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
What the sources say
- Not checked yetcites [30] Saad, 2015, Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302, Eur Urol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomisation was stratified by baseline lactate dehydrogenase level (≤260 IU/L or >260 IU/L), presence of liver metastases (yes or no), ECOG performance status (0/1 or 2), and inclusion of ARPI in protocol-permitted SoC (yes or no).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Randomisation and masking
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium (177Lu) vipivotide tetraxetan ([177Lu]Lu-PSMA-617; 177Lu-PSMA-617) improved radiographic progression-free survival and overall survival when added to protocol-permitted standard of care (SoC) in patients with metastatic castration-resistant prostate cancer (mCRPC).”
- Also stated in: § Introduction · plain
“In the alternate primary endpoints of the phase 3 VISION trial, 177Lu-PSMA-617 prolonged radiographic progression-free survival (rPFS; hazard ratio [HR], 0·40; 99·2% confidence interval [CI]: 0·29, 0·57; p<0·001) and overall survival (OS, 0·62; 95% CI: 0·52, 0·74; p<0·001) when added to protocol-permitted standard of care (SoC) in patients with advanced PSMA-positive mCRPC.12”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Abstract > Background
What the sources say
- Not checked yetcites [12] Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Outcomes were analysed in intention-to-treat populations.”
- Also stated in: § Statistical analysis · plain
“Efficacy outcomes were analysed in intention-to-treat populations; HRQoL outcomes were analysed in the intention-to-treat subset randomised on or after March 5, 2019.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Abstract > Methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Also stated in: § Statistical analysis · plain
In the paper
“These results complement the previously reported primary efficacy endpoints of prolonged rPFS and extended OS with 177Lu-PSMA-617 in the VISION trial.12”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Discussion
What the sources say
- Not checked yetcites [12] Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Radiographic imaging was evaluated in accordance with Response Evaluation Criteria in Solid Tumors 1·1 (RECIST 1·1) and Prostate Cancer Working Group 3 (PCWG3) criteria.”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Study design and participants
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“VISION was an open-label, international, randomised phase 3 trial of the efficacy and safety of 177Lu-PSMA-617 in patients with progressive PSMA-positive mCRPC previously treated with at least one ARPI and one or two taxane-containing regimens, as previously described.12”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Study design and participants
What the sources say
- Not checked yetcites [12] Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“PROs and SSEs were analysed according to assigned treatment group in the PFS analysis set, comprising patients who were randomised after implementation of the measures designed to reduce the drop-out rate in the control group (on or after March 5, 2019).”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Outcomes
What the sources say
- Not checked yetcites [12] Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The authors state this as an assumption.
Patients who did not complete questionnaires because they died or experienced disease progression were assumed to have worsened in health-related quality of life and pain.
“Death and disease progression were included in the prespecified composite endpoints of HRQoL and pain worsening, which were therefore assumed to have worsened in patients who did not complete questionnaires because they died or experienced disease progression.”
The paper relies on this without support.
The VISION population was heavily pre-treated with short remaining life expectancy, so deterioration in health-related quality of life and pain was likely to manifest within the follow-up time.
“The VISION population was heavily pre-treated with short remaining life expectancy, so deterioration in HRQoL and pain was likely to manifest within the follow-up time.”
The paper relies on this without support.
Patients with advanced and highly pre-treated metastatic castration-resistant prostate cancer inevitably experience declining health-related quality of life and death.
“Sustained worsening was not assessed in VISION because of the relatively long interval between PRO assessments (6 or 12 weeks), and because of inevitable declining HRQoL and death in patients with advanced and highly pre-treated mCRPC.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Subsequent studies have further evaluated health-related quality of life and pain outcomes using 177Lu-PSMA- 617 and found that these metrics were both improved as compared to treatment with SOC”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Randomisation and masking
“Randomisation was stratified by baseline lactate dehydrogenase level (≤260 IU/L or >260 IU/L)”
§ Health-related quality of life and pain outcomes in the randomised, open-label, phase 3 VISION study of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer > Methods > Statistical analysis
“stratified by baseline lactate dehydrogenase level (≤260 U/mL or >260 U/mL)”
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Self-citationFizazi, K. S., Carducci, M. A., Smith, M. R., Damião, R., Brown, J. E., Karsh, L. I., Milecki, P., Shore, N. D., Rader, M. E., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,974
Self-citationHofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationEstimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. F. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 932
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C. C., Bangma, C., & Kataja, V. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq174 · Cited by 602
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Self-citationViolet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
Cited by
Sorted by citations
Items 101–125 of 125
A Potent Nickel‐Based STING Agonist Nanodrug Against Prostate Cancer Bone Metastasis
Wang, S., Hou, Y., Wang, J., Li, J., Zhang, C., Gao, R., Li, L., Wang, H., Wang, B., Guo, L., et al. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202525679
Sudprasert, W., Belyakov, O. V., & Tashiro, S. (2026) · Journal of Radiation Research · doi:10.1093/jrr/rrag003
Hornfeck, J., Dahlmann, P., Siegmund, S. C., Gildehaus, F. J., Delker, A., Schmidt-Hegemann, N.-S., Bundschuh, R. A., Zacherl, M. J., Klimek, K., Casuscelli, J., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07817-2
CuET Radiosensitizes FAP-Targeted Radioligand Therapy in Lung Cancer by inhibiting DNA RepairPreprint
Xie, J., Zou, Y., Zheng, Y., Shi, D., Zhou, W., Tian, Y., Wang, L., & Wu, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9032718/v1
Systemic management of spinal metastases: current strategies and future directions
Collin, H., Muller, S., Ferreira, M., & Cancel, M. (2026) · Neurochirurgie · doi:10.1016/j.neuchi.2026.101809
Uwe, H., Cirillo, R., Goulart, M., Hernandez, D., Peristeris, P., Poschenrieder, A., Papaioannou, P., Kanavos, P. G., la Fougère, C. J., & Schaetz, L. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101733
Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer
Şengöz, T., Çimen, O. C., Çelik, A., Gültekin, A., & Şimşek, F. S. (2026) · Anatolian Current Medical Journal · doi:10.38053/acmj.1890714
Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT
Moradpour, M., Hong, C. M., Khan, S., Tuchayi, A. M., Yadav, S., Flavell, R. R., Emmett, L., & Hope, T. A. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.06.007
Genitourinary Cancer: Recent Advances in Diagnosis and Treatment
Zhang, J., & Zimmerman, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-19175-5_20
Chvetzoff, G. (2025) · Dunod eBooks · doi:10.3917/dunod.poisb.2025.01.2898
“New Kid on the Block” 161Tb-FAPI-2286 in Metastatic Papillary Thyroid Cancer
Dash, S., Malasani, V., Yadav, K., Khatana, S., Pandey, D. C., Singh, N., Vatsa, R., Thakral, P., Ashok, P., Kumar, A., et al. (2026) · Clinical nuclear medicine open. · doi:10.1097/nm9.0000000000000082
Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review
Garcia, C. C., Moryousef, J., Pinthus, J. H., & Leong, D. P. (2026) · Cancers · doi:10.3390/cancers18152465
You, Y., Yahaya, N. A., Ramoo, V., Yahya, F., Shi, X., Shang, X., Xu, W., & Jiao, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1868172
Scharf, Z., Muniz, M., Tchitchkan, E., Rami, A., Ravi, P. K., Orme, J. J., Tarhini, A., Jacene, H. A., Sentana‐Lledo, D., & Childs, D. S. (2026) · The Oncologist · doi:10.1093/oncolo/oyag327
Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges
Shi, W., Zhang, L., Feng, X., Liu, J., Li, X., Dong, X., Wong, A. L., Chen, X., Wang, L., & Goh, B.-C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1907065
Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer
Wang, Y., McKenzie, J., & Sandhu, S. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269527
La radiothérapie interne vectorisée : avancées, progrès et perspectives
Vija, L., Bailly, C., Courbon, F., & Deshayes, E. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.07.005
Radiotherapy for Prostate Cancer
Sayegh, M., Tam, A. H., Huang, Z., & Li, Y. R. (2026) · Springer eBooks · doi:10.1007/978-3-031-49762-9_103
Xie, J., Zou, Y., Shi, D., Huang, Y., 周文兰, Tian, Y., Wang, M., Han, P., 吴湖炳, & Wang, L. (2026) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2026.109840
Edouard, L., Papillon, L., Ferrer, L., Godbert, Y., Meyer, M., Prega-Renaud, V., Subreville, C., Anizan, N., Benziane-Ouaritini, N., Gallinato, O., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.09.015
Buonerba, C., & Lorenzo, G. D. (2026) · Current Oncology · doi:10.3390/curroncol33100624
Ha, S., Joo Hyun, O., Park, C., Boo, S. H., Shin, D., Moon, H. W., Yoo, I. R., Kim, I.-H., & Lee, J. Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101328
Sofias, A. M., Derks, Y., Bradbury, M. S., Chen, X. S., Kiessling, F., van Dam, G. M., Weber, W., & Lammers, T. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00983-3
From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology’s New Pillar
Herrmann, K. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.10.1286
Self-citation
Metadata
- Authors
- Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., Calais, J., Nagarajah, J., Wei, X. X., Koshkin, V. S., Beauregard, J.-M., Chang, B., Ghouse, R., DeSilvio, M., Messmann, R. A., & de Bono, J.
- Affiliations
- Université Paris-Saclay (FR)
- Essen University Hospital (DE)
- Universitätsmedizin Rostock (DE)
- University Hospital Münster (DE)
- BC Cancer Agency (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Tulane University (US)
- Weill Cornell Medicine (US)
- Mayo Clinic (US)
- Comprehensive Cancer Centers of Nevada (US)
- Radboud University Medical Center (NL)
- Dana-Farber Cancer Institute (US)
- University of California, San Francisco (US)
- CHU de Québec-Université Laval (CA)
- Radiation Oncology Associates (US)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- Corresponding author
- Fizazi, Karim
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 24
- Issue
- 6
- Pages
- 597-610
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC10641914
- OpenAlex
- W4378800385
- Cited by
- 125
- References
- 34
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 41 · 2023: 9
- FWCI
- 23.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 182 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Oncology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Novartis
- Advanced Accelerator Applications SA
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- 177Lu-PSMA-617, PSMA radioligand therapy, metastatic castration-resistant prostate cancer, health-related quality of life, pain, FACT-P, EQ-5D-5L, Brief Pain Inventory, treatment-related adverse events
- MeSH terms
- Aged, Antineoplastic Combined Chemotherapy Protocols, Bridged-Ring Compounds, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Pain, Quality of Life, Receptors, Androgen, Prostate-Specific Antigen, Taxoids, Androgen Receptor Antagonists, Standard of Care, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
